CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone

Samanta Salvi, Valentina Casadio, Salvatore Luca Burgio, Vincenza Conteduca, Lorena Rossi, Cecilia Menna, Elisa Carretta, Matteo Costantini, Wainer Zoli, Ugo De Giorgi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: We evaluated the role of single nucleotide polymorphisms in the CYP17A1 gene for predicting clinical outcome in castration-resistant prostate cancer (CRPC) patients treated with abiraterone. Methods: Sixty-four patients were genotyped for the selected polymorphisms (rs743572, rs10883783, rs17115100 and rs284849) in CYP17A1. We hypothesized that different genotypes could be associated with progression-free survival (PFS) and overall survival (OS). Results: Statistical analyses highlighted no significant associations between these polymorphisms and clinical outcome. However, individuals with the most common TT genotype for rs10883783 had a 3 months’ longer PFS than individuals with the TA + AA genotype. Conclusions: With the limitation of the retrospective study design and the small sample size, the analyzed polymorphisms do not seem to be correlated with clinical outcome of CRPC patients treated with abiraterone.

Original languageEnglish
Pages (from-to)e264-e269
JournalInternational Journal of Biological Markers
Volume31
Issue number3
DOIs
Publication statusPublished - 2016

Keywords

  • Abiraterone
  • Castration-resistant prostate cancer
  • CYP17A1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Clinical Biochemistry
  • Cancer Research

Fingerprint Dive into the research topics of 'CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone'. Together they form a unique fingerprint.

Cite this